AP Pharma announces allowance of three patents covering APF530


A.P. Pharma announced that the United States Patent and Trademark Office has allowed three new patents covering the Company’s lead product candidate, APF530, which is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The newly allowed patents, when issued, will extend the patent life around APF530 through 2024.

View Comments (0)